News

Center for Laboratory Medicine St. Gallen is the first laboratory to offer Proclarix® from Proteomedix

Schlieren and St. Gallen, Switzerland, April 2, 2020. The Center for Laboratory Medicine in St. Gallen and Proteomedix, the Swiss cancer diagnostics company, announced today that Proclarix®, a new blood-based test for prostate cancer diagnosis, is made available by the Center for Laboratory Medicine St. Gallen (Zentrum für Labormedizin St. Gallen, ZLM). ”Proclarix is...

read more

Kuros Biosciences reports results for the full year 2019

Schlieren (Zurich), Switzerland, March 26, 2020 – Kuros Biosciences successfully delivered on its targets in 2019, increasing sales of MagnetOs fivefold and confirming its successful transition into a fully-fledged orthobiologics company with scientific, clinical, and commercial excellence in bone regeneration. Kuros raised gross proceeds of CHF 12.5 million from a capital...

read more

Kuros strengthens orthobiologics patent portfolio

Schlieren (Zurich), Switzerland, March 18, 2020 – Kuros Biosciences (SIX: KURN) today announced that its subsidiary, Kuros Biosurgery AG, has been granted the US patent, US 10’589’001, entitled ‘Pharmaceutical formulation for use in spinal fusion’. This patent covers the use of parathyroid hormone (PTH) containing matrices for spinal fusion. The granting...

read more

Neurimmune Announces the Initiation of a Phase 1 Study of NI006 for the Treatment of ATTR Cardiomyopathy

Zurich, Switzerland – February 27, 2020 – Neurimmune AG, the discoverer of aducanumab and cinpanemab, announced today enrollment of the first patient in a Phase 1 clinical trial to evaluate NI006 in transthyretin amyloid cardiomyopathy (ATTR cardiomyopathy). NI006 is a human antibody directed against transthyretin amyloid (TTR amyloid) consisting of misfolded...

read more

Proteomedix announces commercial launch of Proclarix® in Europe

Zurich-Schlieren, Switzerland, February 26, 2020. Proteomedix, the Swiss cancer diagnostics company, announced today that Proclarix, its blood-based test for prostate cancer diagnosis, has now been made commercially available in Europe. Proclarix combines proprietary biomarkers and a risk score that accurately identifies an individual patient’s risk for clinically significant prostate cancer. The...

read more